Combination inhaled corticosteroids and long-acting beta2-agonists for acute respiratory tract infections and cough a review of the clinical effectiveness
Although inhaled corticosteroids (ICSs) and long-acting beta2-agonists (LABAs) reduce airway inflammation and mucus secretion which promotes coughing, there remains uncertainty regarding the use of ICS/LABA combination products in patients with persistent non-asthma or non-chronic obstructive pulmon...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2016, 2016
|
| Series: | Rapid response report: summary with critical appraisal
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Although inhaled corticosteroids (ICSs) and long-acting beta2-agonists (LABAs) reduce airway inflammation and mucus secretion which promotes coughing, there remains uncertainty regarding the use of ICS/LABA combination products in patients with persistent non-asthma or non-chronic obstructive pulmonary disease (COPD) coughs. The aim of this review is to summarize evidence of the clinical effectiveness of combination ICSs and LABAs in patients with acute bacterial or viral upper respiratory tract infections, post-infectious or subacute cough, chronic cough, or cough in sarcoidosis to support decision making |
|---|---|
| Item Description: | Caption title. - "CADTH Rapid Response Service.". - "06 July 2016." |
| Physical Description: | 1 PDF file (6 pages) illustration |